SS&H Financial Advisors Inc. Purchases 5,025 Shares of Bristol-Myers Squibb (NYSE:BMY)

SS&H Financial Advisors Inc. grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 10.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 53,900 shares of the biopharmaceutical company’s stock after buying an additional 5,025 shares during the period. Bristol-Myers Squibb accounts for 1.1% of SS&H Financial Advisors Inc.’s portfolio, making the stock its 21st largest position. SS&H Financial Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $3,049,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. Thoroughbred Financial Services LLC grew its holdings in shares of Bristol-Myers Squibb by 9.5% in the second quarter. Thoroughbred Financial Services LLC now owns 10,353 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 901 shares during the last quarter. Envestnet Asset Management Inc. grew its stake in Bristol-Myers Squibb by 1.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,268,887 shares of the biopharmaceutical company’s stock worth $94,227,000 after acquiring an additional 34,643 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its position in shares of Bristol-Myers Squibb by 3.8% during the second quarter. Mesirow Financial Investment Management Inc. now owns 50,808 shares of the biopharmaceutical company’s stock worth $2,110,000 after acquiring an additional 1,882 shares during the period. Citizens Financial Group Inc. RI raised its stake in shares of Bristol-Myers Squibb by 29.7% during the second quarter. Citizens Financial Group Inc. RI now owns 35,203 shares of the biopharmaceutical company’s stock valued at $1,462,000 after acquiring an additional 8,070 shares in the last quarter. Finally, Luts & Greenleigh Group Inc. purchased a new stake in shares of Bristol-Myers Squibb in the second quarter valued at approximately $304,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Up 0.7 %

Shares of NYSE:BMY opened at $55.73 on Wednesday. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The firm has a market capitalization of $113.03 billion, a P/E ratio of -15.52, a P/E/G ratio of 15.20 and a beta of 0.45. The business’s 50-day moving average is $57.44 and its 200 day moving average is $51.76. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.00 earnings per share. On average, research analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.45%. Bristol-Myers Squibb’s payout ratio is -69.08%.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Barclays lifted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research report on Monday, October 7th. Citigroup lifted their price objective on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, November 12th. UBS Group increased their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Finally, BMO Capital Markets increased their price objective on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research note on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.